Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

#8216;203 pivotal trials. The letters do not require additional clinical trials.  Amgen is reviewing the Complete Response Letters and will work with the FDA to determine the appropriate next steps regarding these applications.

Nplate:  The Company announced that the U.S. Prescribing Information for Nplate has been modified to heighten awareness that use is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome.  The Company also discussed the FDA’s recent announcement that they are working to modify the Nplate Risk Evaluation and Mitigation Strategy (REMS) to maintain a focus on physician understanding of appropriate use and potential risks, while eliminating the requirement for restricted distribution of Nplate.  This will reduce the burden on physicians prescribing Nplate.

OncoVEX(GM-CSF):  The Company announced that its Phase 3 trial in patients with malignant melanoma is now fully enrolled.

The Company also announced its decision to terminate its current OncoVEX(GM-CSF) Phase 3 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) to permit significant modification of clinical trial design mandated by the changing therapeutic landscape for patients with SCCHN.

Non-GAAP Financial MeasuresManagement has presented its operating results in accordance with GAAP and on an “adjusted” (or non-GAAP) basis for the three and six months ended June 30, 2011 and 2010. In addition, management has presented its outstanding debt in accordance with GAAP and on an “adjusted” (or non-GAAP) basis as of June 30, 2011.  The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors.  The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning.  These non-GAAP financial measures ar
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Science Corporation , a global leader in automated external ... devices, announced today that the Japan Ministry of ... its Powerheart® G3 AED. The company is partnering with ... Omron is a leading healthcare company dedicated to prevention ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, July 21, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, July ... webcast, please visit Cepheid,s website at www.cepheid.com/investors at ...
Cached Medicine Technology:Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 2Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 3Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 4Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Report ... July 24 Are you an e-patient?,Studies show that ... information. Thanks to Web 2.0, e-patients now have even ... care and learn about,advanced medical technologies. Go to ...
... helps those with HIV who become treatment-resistant, study shows ... offers more evidence that a new AIDS drug brings ... , The drug, known as raltegravir (Isentress), almost doubles ... virus despite being immune to other medications, according to ...
... HTH Worldwide, a global health and,safety services ... its,CityHealth(R) Profiles to Living Abroad.com and its multi-national ... to trusted,medical care in hundreds of destinations around ... information for those living,overseas or about to be ...
... Health and nutrition researcher Frank,Ervolino, ND, investigated ... the risks associated with stimulants. He reports that,Appetite ... Zurich,Pharmaceuticals, makes novel use of an established ingredient ... to lose weight. In fact, in the,U.S., where ...
... the University of Warwick, Dartmouth College, and the University ... influenced by the weight of those around them. Without ... keep up with the weight of the Joneses. For ... of imitative obesity. The researchers will present their results ...
... adoption of interoperable Health Information Technology (HIT) will ... in the U.S. healthcare system," Yul D. Ejnes, MD, ... on Health today. "Unfortunately, without adequate financial incentives, ... the technological curve." Dr. Ejnes, a member of the ...
Cached Medicine News:Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2Health News:Research says fat friends and poor education helps people think thin 2Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... 3.0 x 7.5 x 80 mm. ... II line designed by Harvey A. ... a closed cell sponge which is ... with rounded edges to minimize scleral ...
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
Medicine Products: